News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
536,849 Results
Type
Article (35668)
Company Profile (68)
Press Release (501113)
Multimedia
Podcasts (43)
Webinars (8)
Section
Business (150101)
Career Advice (1616)
Deals (29492)
Drug Delivery (101)
Drug Development (68611)
Employer Resources (114)
FDA (13630)
Job Trends (11527)
News (267682)
Policy (29188)
Tag
Academia (2139)
Accelerated approval (4)
Adcomms (24)
Allergies (79)
Alliances (45841)
ALS (81)
Alzheimer's disease (1310)
Antibody-drug conjugate (ADC) (116)
Approvals (13613)
Artificial intelligence (221)
Autoimmune disease (18)
Automation (10)
Bankruptcy (275)
Best Places to Work (9842)
BIOSECURE Act (16)
Biosimilars (101)
Biotechnology (51)
Bladder cancer (74)
Brain cancer (28)
Breast cancer (251)
Cancer (2034)
Cardiovascular disease (161)
Career advice (1355)
Career pathing (23)
CAR-T (136)
Cell therapy (384)
Cervical cancer (19)
Clinical research (55811)
Collaboration (787)
Company closure (2)
Compensation (486)
Complete response letters (21)
COVID-19 (2635)
CRISPR (39)
C-suite (154)
Cystic fibrosis (78)
Data (2022)
Decentralized trials (1)
Denatured (10)
Depression (44)
Diabetes (261)
Diagnostics (5219)
Digital health (16)
Diversity (4)
Diversity, equity & inclusion (35)
Drug discovery (100)
Drug pricing (107)
Drug shortages (30)
Duchenne muscular dystrophy (91)
Earnings (66327)
Editorial (42)
Employer branding (15)
Employer resources (102)
Events (85054)
Executive appointments (437)
FDA (14814)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (7)
Funding (572)
Gene editing (91)
Generative AI (17)
Gene therapy (275)
GLP-1 (751)
Government (4502)
Grass and pollen (6)
Guidances (142)
Healthcare (15815)
Huntington's disease (22)
IgA nephropathy (25)
Immunology and inflammation (106)
Indications (28)
Infectious disease (2785)
Inflammatory bowel disease (121)
Inflation Reduction Act (7)
Influenza (55)
Intellectual property (91)
Interviews (282)
IPO (14481)
IRA (40)
Job creations (2089)
Job search strategy (1162)
Kidney cancer (9)
Labor market (24)
Layoffs (330)
Leadership (12)
Legal (7481)
Liver cancer (64)
Lung cancer (281)
Lymphoma (133)
Machine learning (9)
Management (34)
Manufacturing (272)
MASH (68)
Medical device (10508)
Medtech (10511)
Mergers & acquisitions (15524)
Metabolic disorders (694)
Multiple sclerosis (71)
NASH (21)
Neurodegenerative disease (87)
Neuropsychiatric disorders (25)
Neuroscience (1799)
NextGen: Class of 2025 (4932)
Non-profit (3377)
Now hiring (19)
Obesity (380)
Opinion (210)
Ovarian cancer (64)
Pain (81)
Pancreatic cancer (82)
Parkinson's disease (134)
Partnered (15)
Patents (214)
Patient recruitment (91)
Peanut (41)
People (31986)
Pharmaceutical (22)
Pharmacy benefit managers (16)
Phase I (16949)
Phase II (24458)
Phase III (19167)
Pipeline (1233)
Policy (140)
Postmarket research (2121)
Preclinical (7031)
Press Release (38)
Prostate cancer (94)
Psychedelics (30)
Radiopharmaceuticals (229)
Rare diseases (337)
Real estate (3352)
Recruiting (49)
Regulatory (19295)
Reports (27)
Research institute (1859)
Resumes & cover letters (244)
Rett syndrome (5)
RNA editing (3)
RSV (47)
Schizophrenia (70)
Series A (97)
Series B (61)
Service/supplier (4)
Sickle cell disease (46)
Special edition (8)
Spinal muscular atrophy (150)
Sponsored (24)
Startups (2280)
State (1)
Stomach cancer (11)
Supply chain (59)
Tariffs (39)
The Weekly (32)
Vaccines (752)
Venture capitalists (29)
Weight loss (268)
Women's health (19)
Worklife (13)
Date
Last 7 days (828)
Last 30 days (2534)
Last 365 days (27748)
2025 (10152)
2024 (30237)
2023 (34685)
2022 (44374)
2021 (48070)
2020 (46002)
2019 (37633)
2018 (28539)
2017 (26524)
2016 (24982)
2015 (29512)
2014 (21768)
2013 (17425)
2012 (18766)
2011 (19663)
2010 (17667)
Location
Africa (658)
Alabama (50)
Alaska (6)
Arizona (147)
Arkansas (9)
Asia (31480)
Australia (5571)
California (5337)
Canada (1750)
China (435)
Colorado (230)
Connecticut (242)
Delaware (139)
Europe (76906)
Florida (820)
Georgia (192)
Hawaii (1)
Idaho (36)
Illinois (406)
India (25)
Indiana (269)
Iowa (8)
Japan (149)
Kansas (78)
Kentucky (19)
Louisiana (10)
Maine (68)
Maryland (822)
Massachusetts (3969)
Michigan (164)
Minnesota (288)
Mississippi (1)
Missouri (70)
Montana (24)
Nebraska (14)
Nevada (51)
New Hampshire (51)
New Jersey (1551)
New Mexico (20)
New York (1495)
North Carolina (814)
North Dakota (6)
Northern California (2392)
Ohio (158)
Oklahoma (8)
Oregon (17)
Pennsylvania (1235)
Puerto Rico (9)
Rhode Island (18)
South America (929)
South Carolina (19)
South Dakota (1)
Southern California (2032)
Tennessee (65)
Texas (764)
United States (19961)
Utah (157)
Virginia (117)
Washington D.C. (46)
Washington State (480)
West Virginia (2)
Wisconsin (43)
536,849 Results for "ava ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
CORRECTING and REPLACING Access Vascular Highlights New Midline Catheter Data at AVA 2024
Data Presented at the AVA Annual Scientific Meeting Shows Significantly Lower Complication and Failure Rates with Access Vascular’s HydroMID® Midline Catheter
October 2, 2024
·
2 min read
Press Releases
Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting
April 29, 2025
·
5 min read
Press Releases
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
March 7, 2025
·
5 min read
Press Releases
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
January 16, 2025
·
6 min read
Press Releases
Access Vascular Highlights New Midline Catheter Data at AVA 2024
October 1, 2024
·
2 min read
Press Releases
CORRECTING and REPLACING Access Vascular Highlights New Midline Catheter Data at AVA 2024
October 2, 2024
·
3 min read
Drug Development
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
Avacta Group plc announces updated clinical data from the First-in-Human Phase 1 trial of the peptide drug conjugate, AVA6000 will be presented at the 2024 American Association for Cancer Research Annual Meeting, taking place in San Diego, California from 5-10 April 2024.
March 5, 2024
·
3 min read
Press Releases
Bacteria in Our Aging Guts Can Elevate Risk of Leukemia
April 24, 2025
·
7 min read
Press Releases
Luminopia Announces FDA Clearance for Patients with Amblyopia Aged 8 to 12 Years
April 22, 2025
·
5 min read
Biotech Bay
23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay
23andMe Holding Co., a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program.
January 30, 2024
·
1 min read
1 of 53,685
Next
